Lupus Nephritis Market Size Forecasted To Achieve 2.8 Billion By 2029 With Steady Growth

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Lupus Nephritis Market Size and Projected Growth Rate?
The market for lupus nephritis has seen robust expansion in the past few years. The market, which is projected to escalate from $1.94 billion in 2024 to $2.09 billion in 2025, will have a compound annual growth rate (CAGR) of 7.9%. This growth during the historic span can be attributed to several factors including escalating investment in lupus nephritis research, a surge in the occurrence of autoimmune diseases, increasing healthcare costs, higher acceptance of biologics, and the rising prevalence of telemedicine.

Expectations are high for the lupus nephritis market size, projected to see robust growth in the upcoming years. By 2029, it's predicted to reach $2.80 billion, with a compound annual growth rate (CAGR) of 7.6%. Several factors contribute to this expected growth, including heightened awareness among physicians, a rise in the usage of biologic therapies, an increase in specialty clinics, accentuated significance of renal transplantation, and improved access to nephrology services. Key trends for the forecast period are enhancements in biologic therapies, personalized treatment strategies, innovative diagnostic biomarkers, expanded clinical trials, and advances in stem cell therapy.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22044

What Are the Major Segments in the Lupus Nephritis Market?
The lupus nephritis market covered in this report is segmented -

1) By Stage: Class 1, Class 2, Class 3, Other Stages
2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs
3) Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis.
2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition.
3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation.
4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

What Are The Driving Lupus Nephritis Market Evolution?
The surge in genetic predisposition is anticipated to fuel the expansion of the lupus nephritis market in the future. Genetic predisposition pertains to the genetically inherited traits within an individual, heightening their probability of being afflicted by certain diseases or conditions. This growing prevalence is attributed to factors such as heredity, environmental influences, and alterations in specific genes. This increase in genetic predisposition plays an indispensable role in the onset of lupus nephritis, highlighting the effect of inherited genetic elements in autoimmune diseases, particularly those targetting kidney functionality. For example, in October 2024, as reported by the Cystic Fibrosis Trust, a charity based in the UK, the UK CF Registry reported 11,148 registered patients in 2022, which escalated to 11,318 in 2024, representing a 1.52% increase in individuals diagnosed with cystic fibrosis (CF). Consequently, the escalating prevalence of genetic predisposition is propelling the growth of the lupus nephritis market.

Which Firms Dominate The Lupus Nephritis Market Segments?
Major companies operating in the lupus nephritis market are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Genentech, Astrazeneca PLC, Biocon Biologics, Hanmi Pharmaceutical Co. Ltd., Sana Biotechnology Inc., RemeGen Co. Ltd., Aurinia Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Equillium Inc., Anthera Pharmaceuticals Inc., Atara Biotherapeutics Inc., Artiva Biotherapeutics, Caribou Biosciences, Nkarta Inc., Adicet Bio Inc., Lupus Research Alliance, Kyverna Therapeutics Inc., Kezar Life Sciences, Bionxt Solutions.

What Trends Are Expected to Dominate the Lupus Nephritis Market in the Next 5 Years?
Leading firms in the lupus nephritis market are concentrating on the advancement of second-generation calcineurin inhibitors to amplify the efficacy of treatments and promote better long-term kidney results for patients. These inhibitors play a crucial role in lupus nephritis by modulating immune responses to reduce inflammation and avoid kidney damage. For example, in September 2024, the Japanese Ministry of Health, Labour, and Welfare granted approval to Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company based in Canada, for the use of LUPKYNIS (voclosporin) in lupus nephritis treatment. The endorsement for voclosporin, allowing its use together with mycophenolate mofetil (MMF), was facilitated by positive data from the AURORA Clinical Program indicating its safety and effectiveness. This approval is a noteworthy step towards expanding treatment possibilities for lupus nephritis patients in Japan, thus making strides in disease management and results.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

Which Is The Largest Region In The Lupus Nephritis Market?
Asia-Pacific was the largest region in the lupus nephritis market in 2024. The regions covered in the lupus nephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Lupus Nephritis Market?
2. What is the CAGR expected in the Lupus Nephritis Market?
3. What Are the Key Innovations Transforming the Lupus Nephritis Industry?
4. Which Region Is Leading the Lupus Nephritis Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.